ABL1 H396P

CI-VAR-00001920Explore in graph →NP_005148.2:p.His396ProNM_005157.5:c.1187A>CCIViC 1531

Curated evidence

Evidence by cancer (11 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–11 of 11 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Lymphoblastic Leukemia1
BCR::ABL1 Fusion AND ABL1 H396P	Bosutinib	Predictive	D	Does Not Support Resistance	2	submitted	EID4379 In an in vitro kinase study, the recombinant ABL1 H396P mutant kinase did not demonstrate resistance to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 1 and 1) when compared to wil… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC	civic
Chronic Myeloid Leukemia, BCR-ABL1 Positive7
BCR::ABL1 Fusion AND ABL1 H396P	Axitinib	Predictive	D	Does Not Support Resistance	2	accepted	EID7770 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed lower incorporation when harboring fusions with the H…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm3
BCR::ABL1 Fusion AND ABL1 H396P	Dasatinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID9084 In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to dasatinib treatment (IC50: 8.9 nM) as co… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 H396P	Imatinib	Predictive	D	Supports Resistance	3	accepted	EID7847 In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib treatment (IC50: >2000.0 nM) as compared t… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 H396P	Bafetinib + NilotinibSubstitutes	Predictive	D	Does Not Support Resistance	3	accepted	EID7846 In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib (INNO-406) treatme… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic